A second gut-hormone receptor (glucose-dependent insulinotropic polypeptide) that, alongside GLP-1, influences blood sugar and appetite. Tirzepatide acts on both GIP and GLP-1 receptors (a "dual agonist") which is the mechanistic reason it tends to produce somewhat greater average weight loss than GLP-1-only drugs like semaglutide. Newer pipeline drugs add even more targets.
Related terms: GLP-1 (glucagon-like peptide-1) · Tirzepatide · Semaglutide
See also: Wegovy vs. Zepbound